⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVPH News
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
globenewswire.com
RVPH
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
globenewswire.com
RVPH
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
globenewswire.com
RVPH
Form 8-K
sec.gov
RVPH
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
globenewswire.com
RVPH
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
globenewswire.com
RVPH
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
globenewswire.com
RVPH
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
RVPH
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
globenewswire.com
RVPH
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
globenewswire.com
RVPH